|
1
|
Einama T, Takihata Y, Aosasa S, Konno F, Kobayashi K, Yonamine N, Fujinuma I, Tsunenari T, Nakazawa A, Shinto E, et al: Prognosis of pancreatic cancer based on resectability: A single center experience. Cancers (Basel). 15:11012023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prudner BC, Rathore R, Robinson AM, Godec A, Chang SF, Hawkins WG, Hirbe AC and Van Tine BA: Arginine starvation and docetaxel induce c-Myc-Driven hENT1 surface expression to overcome gemcitabine resistance in ASS1-negative tumors. Clin Cancer Res. 25:5122–5134. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Orlandi A, Calegari MA, Martini M, Cocomazzi A, Bagalà C, Indellicati G, Zurlo V, Basso M, Cassano A, Larocca LM and Barone C: Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: Everything was not too bad back when everything seemed worse. Clin Transl Oncol. 18:988–995. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brierley JD, Gospodarowicz MK and Wittekind C: TNM classification of malignant tumours. 8th edition. Oxford; pp. 83–90. 2017
|
|
8
|
Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et al: Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fukui H, Kou C and Fujioka M: Effective multidisciplinary therapy mainly using S-1+ gemcitabine (GEM) for a case of pancreatic body cancer with multiple liver metastases. Gan To Kagaku Ryoho. 39:1727–1731. 2012.(In Japanese). PubMed/NCBI
|
|
10
|
Ohkawa S, Sakamoto Y and Ueno M: A case of pancreatic body cancer with multiple liver metastases experiencing long-term response by gemcitabine plus erlotinib therapy. Gan To Kagaku Ryoho. 40:785–788. 2013.(In Japanese). PubMed/NCBI
|
|
11
|
Shelemey PT, Amaro CP, Ng D, Falck V and Tam VC: Metastatic pancreatic cancer with complete response to FOLFIRINOX treatment. BMJ Case Rep. 14:e2383952021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao X, Wang X, Sun W, Cheng K, Qin H, Han X, Lin Y, Wang Y, Lang J, Zhao R, et al: Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. Biomaterials. 158:44–55. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bird NTE, Elmasry M, Jones R, Psarelli E, Dodd J, Malik H, Greenhalf W, Kitteringham N, Ghaneh P, Neoptolemos JP and Palmer D: Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. Br J Surg. 104:328–336. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brandi G, Deserti M, Vasuri F, Farioli A, Degiovanni A, Palloni A, Frega G, Barbera MA, de Lorenzo S, Garajova I, et al: Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients. Oncologist. 21:600–607. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamada R, Mizuno S, Uchida K, Yoneda M, Kanayama K, Inoue H, Murata Y, Kuriyama N, Kishiwada M, Usui M, et al: Human equilibrative nucleoside transporter 1 expression in endoscopic ultrasonography-guided fine-needle aspiration biopsy samples is a strong predictor of clinical response and survival in the patients with pancreatic ductal adenocarcinoma undergoing gemcitabine-based chemoradiotherapy. Pancreas. 45:761–771. 2016. View Article : Google Scholar : PubMed/NCBI
|
